Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival bearing tumors derived from Brca1-deficient ovarian cancer cells
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) with small molecules has been shown to be an effective treatment for ovarian cancer with BRCA mutations. Here, we report the in vivo administration of siRNA to Parp1 in mouse models of ovarian cancer. A unique member of the li...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2011
|
| Online Access: | http://hdl.handle.net/1721.1/65350 https://orcid.org/0000-0003-1465-1691 https://orcid.org/0000-0002-1293-2097 |